尼莫同联合依达拉奉注射液治疗缺血性脑卒中患者的临床疗效及安全性

Clinical Efficacy and Safety of Nimotop Combined with Edaravone Injection in the Treatment of Ischemic Stroke Patients

目的:评价尼莫同与依达拉奉注射液联合治疗缺血性脑卒中患者的临床疗效及安全性。方法:选取在某院接受缺血性脑卒中治疗的患者100例,按照治疗方法的不同,将其均分为单一治疗组和联合治疗组两个组别,比较两组治疗的临床疗效、治疗前后的神经功能缺损情况。结果:联合治疗组治疗的总有效率显著高于单一治疗组(P<0.05),治疗后7d、14d联合治疗组的神经功能缺损评分的改善情况显著优于单一治疗组(P<0.05),且联合治疗组患者的不良反应率显著低于单一治疗组(P<0.05)。结论:尼莫地平注射液和依达拉奉注射液联合治疗缺血性脑卒中具有更好的临床疗效,且不良反应率低,值得推广。

Objective:To evaluate the clinical efficacy and safety of Nimotop combined with edaravone injection in the treatment of ischemic stroke patients.Methods:100 patients who underwent ischemic stroke in a hospital were divided into two groups:single treatment group and combination treatment group according to different treatment methods.The clinical effect and the neurological defects before and after treatment of the two groups was compared.Results:The total effective rate of the combination treatment group was significantly higher than that of the single treatment group(P<0.05).The improvement of the neurological deficit score in the combination treatment group at 7d and 14d after treatment,significantly better than that of the single treatment group(P<0.05).The adverse reaction rate of the patients in the combination group was significantly lower than that in the single treatment group(P<0.05).Conclusion:Nimotop injection combined with edaravone injection has better clinical efficacy in the treatment of ischemic stroke,and the adverse reaction rate is low,which is worthy of promotion.